

DAFTAR PUSTAKA

- Abbas, A. K., Lichtman, A. H., & Pillai, S., 2007. *Cellular and Molecular Immunology*. 6th ed. Elsevier-Saunders, Philadelphia.
- Aslan, A., Aslan, C., Zolbanin, N. M., & Jafari, R., 2021. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. *Pneumonia*, 13(1): 1-15.
- Atmar, R. L., Lyke, K. E., Deming, M. E., Jackson, L. A., Branche, A. R., Sahly, H. M. E., Rostad, C. A., Martin, J. M., Johnston, C., Rupp, R. E., Mulligan, M. J., Brady, R. C., Frenck, R. W., Bäcker, M., Kottkamp, A. C., Babu, T. M., Rajakumar, K., Edupuganti, S., Dobrzynski, D., Beigel, J. H. 2022. Homologous and heterologous COVID-19 booster vaccinations. *New England Journal of Medicine*, 386(11), 1046–1057. <https://doi.org/10.1056/nejmoa2116414>
- Au, W.Y. and Cheung, P., 2022. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. *BMJ*, p. e069989.
- Baker, K.F. *et al.*, 2021. National Early Warning Score 2 (NEWS2) to identify inpatient COVID-19 deterioration: a retrospective analysis. *Clinical Medicine*. 21(2): pp. 84–89.
- Barros- Martins J, Hammerschmidt SI, Cossmann A, et al., 2021. Immune responses against SARS- CoV- 2 variants after heterologous and homologous ChAdOx1 nCoV- 19/BNT162b2 vaccination. *Nat Med*. 27:1525- 1529. 10.1038/s41591-021-01449-9.
- Bellamkonda, N. *et al.*, 2022. Immune response to SARS-COV-2 vaccines. *Biomedicines*. 10(7): 1464.
- Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., Myers, R., Campbell, C. N. J., Amirthalingam, G., Edmunds, M., Zambon, M., Brown, K. E., Hopkins, S., Chand, M., & Ramsay, M., 2021. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England Journal of Medicine*, 385(7), 585–594. <https://doi.org/10.1056/nejmoa2108891>
- Bhardwaj, A. *et al.*, 2021. COVID-19: Immunology, immunopathogenesis and potential therapies. *International Reviews of Immunology*. 41(2): 171–206.
- Burhan, E., Susanto, A. D., Isbaniah, F., Nasution, S. A., Ginanjar, E., Pitoyo, C. W. *et al.*, 2022. *Pedoman Tatalaksana COVID-19 Edisi 4*. Jakarta: Diterbitkan bersama oleh PDPI, PERKI, PAPDI, PERDATIN, IDAI
- Chen, Y. *et al.*, 2022. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. *Clinical Microbiology and Infection*. 28(3): pp. 410–418.
- Chida, D., & Iwakura, Y., 2007. Peripheral TNF α , but not peripheral IL-1, requires endogenous IL-1 or TNF α induction in the brain for the febrile response. *Biochem Biophys Res Commun*. 364:765–770.
- Clemens, S. A., Weckx, L., Clemens, R., Almeida Mendes, A. V., Ramos Souza, A., Silveira, M. B. V., da Guarda, S. N. F., de Nobrega, M. M., de Moraes Pinto, M. I., Gonzalez, I. G. S., Salvador, N., Franco, M. M., de Avila Mendonça, R. N., Queiroz Oliveira, I. S., de Freitas Souza, B. S., Fraga, M., Aley, P., Bibi, S., Cantrell, L., Dejnirattisai, W., 2022. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine

- in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. *Lancet*, 399(10324), 521–529.
- Dahlan, M.S., 2019. *Besar Sampel dalam Penelitian Kedokteran dan Kesehatan*. Epidemiologi Indonesia, Jakarta.
- De Socio, G. V., Gidari, A., Sicari, F., Palumbo, M., & Francisci, D., 2021. National Early Warning Score 2 (NEWS2) better predicts critical Coronavirus Disease 2019 (COVID-19) illness than COVID-GRAM, a multi-centre study. *Infection*, 49(5), 1033–1038. <https://doi.org/10.1007/s15010-021-01620-x>
- Desai A, Desai P, Mehta J, et al., 2021. Measuring the impact of a single dose of ChAdOx1 nCoV-19 (recombinant) coronavirus vaccine on hospital stay, ICU requirement, and mortality outcome in a tertiary care centre. *Int J Infect Dis*. 113:282-287. doi: 10.1016/j.ijid.2021.10.032.
- Diamond, M.S. and Kanneganti, T.-D., 2022. Innate immunity: the first line of defense against SARS-CoV-2. *Nature Immunology*. 23(2): 165–176.
- Dunkle, L. M., Kotloff, K. L., Gay, C., Áñez, G., Adelglass, J., 2022. Efficacy and safety of NVX-COV2373 in adults in the United States and Mexico. *The New England Journal of Medicine*, 386(6), 531–543. <https://doi.org/10.1056/nejmoa2116185>.
- El-Sadr, W., Vasan, A., & El-Mohandes, A., 2023. Facing the new COVID-19 reality. *The New England Journal of Medicine*, 388(5): 385–387.
- Fan, Y. J., Chan, K. H., & Hung, I. F., 2021. Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3. *Vaccines*, 9(9), 989. <https://doi.org/10.3390/vaccines9090989>.
- Fang, E. et al., 2022. Advances in COVID-19 mRNA vaccine development. *Signal Transduction and Targeted Therapy*. 7(1).
- Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *Lancet* 2022; 399: 924-44.
- Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N., 2022. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. *Clin Microbiol Infect*. 28(2):202-221. doi: 10.1016/j.cmi.2021.10.005.
- Genç Bahçe, Y., Acer, Ö. & Özüdoğru, O., 2023. Effectiveness of Inactivated and mRNA COVID-19 Vaccines Against SARS-CoV-2 Infection, Severe Disease and Mortality in the Geriatric Population. *Curr Microbiol* 80, 206. <https://doi.org/10.1007/s00284-023-03322-z>.
- Gidari, A., De Socio, G. V., Sabbatini, S., & Francisci, D., 2020. Predictive value of National Early Warning Score 2 (NEWS2) for intensive care unit admission in patients with SARS-CoV-2 infection. *Infectious Diseases*, 52(10), 698–704. <https://doi.org/10.1080/23744235.2020.1784457>
- Graña, C., Ghosn, L., Evrenoglou, T., Jarde, A., Minozzi, S., Bergman, H., et al., 2022. Efficacy and safety of COVID-19 vaccines. *Cochrane Database Systematic Review*. 12: 1-302.
- Harder, T., Koch, J., Vygen-Bonnet, S., Külper-Schiek, W., Pilic, A., Reda, S., et al., 2021. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. *Euro Surveill*, 26(28): 210-563.
- Hasanpourghadhi, M., 2021. COVID-19 Vaccines Based on Adenovirus Vectors. *Trends in Biochemical Science*. 46: 1-16.

- Hay, K. A., Hanafi, L.A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M. *et al.*, 2017. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T cell therapy. *Blood*.
- Heinz, F.X. and Stiasny, K., 2021. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. *Npj Vaccines*. 6(1).
- Higdon, M.M. *et al.*, 2022. A systematic review of coronavirus disease 2019 vaccine efficacy and effectiveness against severe acute respiratory syndrome coronavirus 2 infection and disease. *Open Forum Infectious Diseases*. 9(6).
- Horita, N., & Fukumoto, T., 2022. Global case fatality rate from COVID-19 has decreased by 96.8% during 2.5 years of the pandemic. *Journal of Medical Virology*. 95(1).
- Hunter, C. A., & Jones, S. A., 2015. IL-6 as a keystone cytokine in health and disease. *Nat Immunol*. 16: 448–457.
- Jiang, Y., Xu, J., Zhou, C., Wu, Z., Zhong, S., Liu, J. *et al.*, 2005. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. *Am J Respir Crit Care Med*. 171: 850–857.
- Juniper, M., 2022. NEWS2, patient safety and hypercapnic respiratory failure. *PubMed*, 22(6), 518–521. <https://doi.org/10.7861/clinmed.2022-0352>
- Kementerian Kesehatan Republik Indonesia, 2023. *Infeksi Emerging: COVID-19*. <https://infeksiemerging.kemkes.go.id/dashboard/covid-19>. Date of access: 10 September 2023.
- Khalid, K. and Poh, C.L., 2023. The development of DNA vaccines against SARS-CoV-2. *Advances in Medical Sciences*, 68(2), pp. 213–226.
- Kyriakidis, N.C. *et al.*, 2021. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. *Npj Vaccines*. 6(1).
- Lamers, M.M. and Haagmans, B.L., 2022. SARS-CoV-2 pathogenesis. *Nature Reviews Microbiology*. 20(5): 270–284.
- Law, Martin *et al.*, 2023. Efficacy and effectiveness of inactivated vaccines against symptomatic COVID-19, severe COVID-19, and COVID-19 clinical outcomes in the general population: a systematic review and meta-analysis. *The Lancet Regional Health – Western Pacific*, 37: 100788.
- Leung, N., 2023. Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial. *The Lancet*, 4(9).
- Li, Z. *et al.*, 2021. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. *Frontiers in Immunology*, 12. <https://doi.org/10.3389/fimmu.2021.802858>
- Mangalmurti, N., & Hunter, C. A., 2020. Cytokine Storms: Understanding COVID-19. *Immunity*. 53: 19-25.
- Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, Casado I, Navascués A, Burgui C, Ezpeleta C, Castilla J, Guevara M., 2022. Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022. *Euro Surveill*. 28(5):2200337. doi: 10.2807/1560-7917.ES.2023.28.5.2200337.
- Menegale, F., Manica, M., Zardini, A., Guzzetta, G., *et al.*, 2023. Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-

- analysis. *JAMA network open*, 6(5), e2310650. <https://doi.org/10.1001/jamanetworkopen.2023.10650>
- Minkoff, J.M., & Tenover, B.R., 2023. Innate immune evasion strategies of SARS-CoV-2. *Nature Reviews Microbiology*. 21(3): 178–194.
- Mistry, P. *et al.*, 2022. SARS-COV-2 variants, vaccines, and host immunity. *Frontiers in Immunology*.12: 809244.
- Moghadas, S. M., Vilches, T. N., Zhang, K., Wells, C. R., Shoukat, A., Singer, B. H. *et al.*, 2021. The impact of vaccination on coronavirus disease 2019 (covid-19) outbreaks in the United States. *Clin Infect Dis*. 73(12): 2257-64.
- Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., *et al.*, 2021. Post-acute COVID-19 syndrome. *Nat Med*. 27(4): 601-15.
- National Institutes of Health, 2023. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. *National Institutes of Health*. Retrieved October 21, 2023, from <https://www.covid19treatmentguidelines.nih.gov/>
- Orlandi, C., Stefanetti, G., Barocci, S., Buffi, G., Diotallevi, A., Rocchi, E., Ceccarelli, M., Peluso, S., Vandini, D., Carlotti, E., Magnani, M., Galluzzi, L., & Casabianca, A., 2023. Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay. *Viruses*, 15(5), 1162.
- Paludan, S.R., & Mogensen, T.H., 2022. Innate immunological pathways in COVID-19 pathogenesis. *Science Immunology*. 7(67): 5505.
- Pemerintah Kabupaten Sleman (Pemkab Sleman), 2023. *Dashboard informasi COVID-19 Kabupaten Sleman*. <https://covidtracer.slemankab.go.id/dashboard2/>. Date of access 16 September 2023.
- Piernas, C., *et al.*, 2022. Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study. *The Lancet Diabetes & Endocrinology*, 10(8), 571–580. [https://doi.org/10.1016/s2213-8587\(22\)00158-9](https://doi.org/10.1016/s2213-8587(22)00158-9)
- Pilishvili T, Fleming-Dutra KE, Farrar JL, *et al.*, 2021. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel. *MMWR Morb Mortal Wkly Rep* 70:753–758. DOI: <http://dx.doi.org/10.15585/mmwr.mm7020e2>
- Primorac, D., *et al.*, 2022. Adaptive immune responses and immunity to SARS-COV-2. *Frontiers in Immunology*. 13: 848582.
- Purwanti, E.D., Ronoatmojo, S., 2023. Association between COVID-19 Vaccination Status with Severity of Confirmed COVID-19 Patients Period of January-July 2022 in Indonesia. *Jurnal Ilmu Kesehatan Masyarakat*, 14(1):13-26. doi.org/10.26553/jikm.2023.14.1.13-26
- Romanelli, D., Farrell MW., 2023. AVPU Score. *Stat Pearls - NCBI Bookshelf*. <https://www.ncbi.nlm.nih.gov/books/NBK538431/>
- Royal College of Physicians, 2017. *National Early Warning Score (NEWS) 2: standardizing the assessment of acute-illness severity in the NHS*. <https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2>. Date of access 10 September 2023.
- Rummel, C., Sachot, C., Poole, S., & Luheshi, G.N., 2006. Circulating interleukin-6 induces fever through a STAT3-linked activation of COX-2 in the brain. *Am J Physiol Regul Integr Comp Physiol*. 291:1316–1326.

- Sadarangani, M., Marchant, A. and Kollmann, T.R., 2021. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. *Nature Reviews Immunology*. 21(8): 475–484.
- Scott, L. J., Tavaré, A., Hill, L., Jordan, L., Juniper, M., Srivastava, S. K., Redfern, E., Little, H., & Pullyblank, A., 2022. Prognostic value of National Early Warning Scores (NEWS2) and component physiology in hospitalised patients with COVID-19: a multicentre study. *Emergency Medicine Journal*, 39(8), 589–594. <https://doi.org/10.1136/emered-2020-210624>
- Sette, A., & Crotty, S., 2021. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell*. 184(4): 861-880.
- Silva, M.J.A. *et al.*, 2022. Adaptive immunity to SARS-CoV-2 infection: A systematic review. *Frontiers in Immunology*. 13: 101-198.
- Sofwan, F., Juniati N., Adiyanto, B., 2022. Validasi National Early Warning Score 2 (NEWS2) Dewasa Untuk Memprediksi Mortalitas Pasien COVID-19 Di RSUP Sardjito Yogyakarta. *Jurnal Komplikasi Anestesi*.
- Ssentongo, P., Ssentongo, A.E., Voleti, N. *et al.*, 2022. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. *BMC Infectious Disease*, 22: 439. <https://doi.org/10.1186/s12879-022-07418-y>
- Stuart, A., *et al.* 2022. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjunct vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. *The Lancet*, 399 (10319) 36 - 49.
- Susilo, A., Martin Rumende, C., Pitoyo, C.W., Djoko Santoso, W., Yulianti, M., Sinto, R., Singh, G. *et al.*, 2020. Coronavirus disease 2019: tinjauan literatur terkini. *Jurnal Penyakit Dalam Indonesia*. 7(1): 45-67.
- Tan CS, Collier AY, Yu J, *et al.* Durability of Heterologous and Homologous COVID-19 Vaccine Boosts. *JAMA Network Open*. 2022;5(8):e2226335. doi:10.1001/jamanetworkopen.2022.26335
- Tanaka T, Narazaki M, Kishimoto T., 2016. Immunotherapeutic implications of IL-6 blockade for cytokine storm. *Immunotherapy*. 8(8): 959-70.
- Tanriover M.D., Doğanay H.L., Akova M., Güner H.R., Azap A., Akhan S., *et al.*, 2021. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *The Lancet*. 399(10323):436.
- Teijaro, J.R. and Farber, D.L., 2021. COVID-19 vaccines: modes of immune activation and future challenges. *Nature Reviews Immunology*. 21(4):195–197.
- Upreti, S. and Samant, M., 2022. A review on immunological responses to SARS-COV-2 and various COVID-19 vaccine regimens. *Pharmaceutical Research*. 39(9): 2119–2134.
- Vanaparthi, R. *et al.*, 2021. Review of COVID-19 viral vector-based vaccines and COVID-19 variants. *Le Infezioni in Medicina : Rivista Periodica Di Eziologia, Epidemiologia, Diagnostica, Clinica E Terapia Delle Patologie Infettive*. 29(3): 328–338.
- Wang, S., Liang, B., Wang, W., Li, L., Feng, N., *et al.*, 2023. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. *Signal Transduction and Targeted Therapy*, 8(1): 149-163.

- Welch, J. J., Dean, J., & Hartin, J., 2022. Using NEWS2: an essential component of reliable clinical assessment. *PubMed*, 22(6), 509-513. <https://doi.org/10.7861/clinmed.2022-043>
- Williams, B., 2022. The National Early Warning Score: from concept to NHS implementation.. *Clinical Medicine Journal*, 22(6): 499–505.
- World Health Organization (WHO), 2023. *Coronavirus disease (COVID-19) pandemic*. Available at: <https://www.who.int/europe/emergencies/situations/covid-19>. Date of access: 6 September 2023.
- World Health Organization, 2021. *Interim recommendations for heterologous COVID-19 vaccine schedules*. <https://iris.who.int/bitstream/handle/10665/350635/WHO-2019-nCoV-vaccines-SAGE-recommendation-heterologous-schedules-2021.1-eng.pdf?sequence=1>. Date of access: October 3, 2023.
- World Health Organization, 2021. *Living Guidance: COVID-19 Clinical Management*. <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2>
- World Health Organization, 2023. *8th Intra-Action Review (IAR) COVID-19: Sustaining preparedness and resilience for emerging threats*. [https://www.who.int/indonesia/news/detail/11-09-2023-8th-intra-action-review-\(iar\)-covid-19-sustaining-preparedness-and-resilience-for-emerging-threats](https://www.who.int/indonesia/news/detail/11-09-2023-8th-intra-action-review-(iar)-covid-19-sustaining-preparedness-and-resilience-for-emerging-threats). Date of access 28 Agustus 2023.
- World Health Organization, 2023. *Coronavirus disease (COVID-19): Vaccines and vaccine safety*. [https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-\(covid-19\)-vaccines](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines). Date of access 8 September 2023.
- Wu, D., & Yang, X.O., 2020. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib. *J Microbiol Immunol Infect*. 53(3):368-370
- Wu, D., Rao, Q., & Zhang, W., 2021. The natural course of COVID-19 patients without clinical intervention. *J Med Virol*. 93(9): 5527-37.
- Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C. *et al.*, 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*. 8: 420–422.
- Yang, Z., Jiang, Y., Li F., Liu, D., Lin, T.F., *et al.*, 2023. Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. *The Lancet Microbe*. 4(4): 236–246.
- Zhang, J., Dong, X., Liu, G., & Gao, Y., 2022. Risk and protective factors for COVID-19 morbidity, severity, and mortality. *Clinical Reviews in Allergy & Immunology*, 64(1), 90–107.